Genetic Diversity and in vitro Activity of Aztreonam/Avibactam and Ceftazidime/Avibactam Against Carbapenem-Resistant Enterobacterales: A Multi-Center Study in Southwest China

被引:4
|
作者
Sun, Shan [1 ]
Chen, Kai [2 ]
Kong, Xuehua [2 ]
Tian, Wenjun [3 ]
Niu, Siqiang [1 ]
机构
[1] Chongqing Med Univ, Dept Lab Med, Affiliated Hosp 1, Chongqing, Peoples R China
[2] Chongqing Med Univ, Coll Lab Med, Chongqing, Peoples R China
[3] Shandong Univ, Shandong Prov Hosp, Cheeloo Coll Med, Dept Clin Lab Med, Jinan, Shandong, Peoples R China
来源
INFECTION AND DRUG RESISTANCE | 2022年 / 15卷
基金
中国国家自然科学基金;
关键词
carbapenem-resistant Enterobacterales; carbapenemase genes; aztreonam/avibactam; ceftazidime/avibactam; KLEBSIELLA-PNEUMONIAE; MOLECULAR EPIDEMIOLOGY; ANTIBIOTIC-RESISTANCE; AZTREONAM-AVIBACTAM; INFECTION; STRAINS; CRE;
D O I
10.2147/IDR.S357396
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Purpose: This study aimed to understand the distribution characteristics of carbapenemase genes and assess the antimicrobial activities of aztreonam/avibactam (ATM/AVI) and ceftazidime/avibactam (CAZ/AVI) against carbapenem-resistant Enterobacterales (CRE) isolates in Chongqing, Southwest China. Methods: CRE isolates and their clinical information were collected from 22 hospitals covering all the five regions across Chongqing between January 1, 2016 and December 31, 2017. PCR was used to screen for common carbapenemase genes. And minimum inhibitory concentrations (MICs) were determined by broth microdilution method. Results: A total of 312 unduplicated CRE isolates (eg, 206 Klebsiella pneumoniae, 43 Escherichia coli, and 42 Enterobacter cloacae) were collected during the two-year study period. Among these CRE isolates, 92.3% carried carbapenemase genes, with a majority of isolates carrying single bla(KPC-2) (47.1%) or single bla(NDM/IPM) (36.2%) and 8.9% of isolates carrying two or three carbapenemase genes. Notably, 95.6% (197/206) K. pneumoniae, 86.0% (37/43) E. coli and 88.1% (37/42) E. cloacae harbored carbapenemase genes. In addition, bla(KPC-2) was prevalent in K. pneumoniae (70.4%), while bla(NDM) was predominant in E. coli (83.7%) and E. cloacae (78.6%). Besides, only metallo-beta-lactamase (MBL) genes were detected in the CRE isolates from children. Overall, 0.0%, 48.1%, 59.0%, 61.5% and 63.1% of the CRE isolates were resistant to ATM/AVI, CAZ/AVI, nitrofurantoin, amikacin and trimethoprim/sulfamethoxazole, respectively. 99.7% of the total 312 isolates could be killed by ATM/AVI with the MIC 1 mu g/mL, whereas CAZ/AVI showed good antibacterial activity (98.0% susceptible) against the bla(KPC-2)-carriers with the MIC50/90 values of 1/4 mu g/mL. Conclusion: The distribution features of carbapenemase genes in Chongqing were comprehensively illustrated in terms of species and sources of CRE for the first time in this multi-center study that covered all the geographical locations across Chongqing. ATM/AVI showed superior activity against all CRE isolates regardless of their genotype, whereas CAZ/AVI was active against almost all KPC-producers.
引用
收藏
页码:2243 / 2251
页数:9
相关论文
共 50 条
  • [31] Ceftazidime-Avibactam for the Treatment of Carbapenem-Resistant Klebsiella Pneumoniae Infection: A Retrospective, Single Center Study
    Yu, Chen-Huan
    Tsai, Mao-Song
    Liao, Chun-Hsing
    Yang, Chia-Jui
    INFECTION AND DRUG RESISTANCE, 2024, 17 : 5363 - 5374
  • [32] In vitro activity of ceftazidime/avibactam against ceftazidime-resistant Enterobacterales and Pseudomonas aeruginosa from hospitalised patients in Germany
    Kresken, Michael
    Korte-Berwanger, Miriam
    Pfennigwerth, Niels
    Gatermann, Soren G.
    JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE, 2021, 25 : 337 - 338
  • [33] Changing Epidemiology of Carbapenemases Among Carbapenem-Resistant Enterobacterales From United States Hospitals and the Activity of Aztreonam-Avibactam Against Contemporary Enterobacterales (2019-2021)
    Sader, Helio S.
    Mendes, Rodrigo E.
    Carvalhaes, Cecilia G.
    Kimbrough, John H.
    Castanheira, Mariana
    OPEN FORUM INFECTIOUS DISEASES, 2023, 10 (02):
  • [34] In vitro, in vivo and clinical studies comparing the efficacy of ceftazidime-avibactam monotherapy with ceftazidime-avibactam-containing combination regimens against carbapenem-resistant Enterobacterales and multidrug-resistant Pseudomonas aeruginosa isolates or infections: a scoping review
    Aslan, Abdullah Tarik
    Ezure, Yukiko
    Horcajada, Juan Pablo
    Harris, Patrick N. A.
    Paterson, David L.
    FRONTIERS IN MEDICINE, 2023, 10
  • [35] Ceftazidime-Avibactam as Salvage Therapy in Pediatric Liver Transplantation Patients with Infections Caused by Carbapenem-Resistant Enterobacterales
    Wang, Weili
    Wang, Rongrong
    Zhang, Yuntao
    Zeng, Lei
    Kong, Haisen
    Bai, Xueli
    Zhang, Wei
    Liang, Tingbo
    INFECTION AND DRUG RESISTANCE, 2022, 15 : 3323 - 3332
  • [36] Assessing the in vitro impact of ceftazidime on aztreonam/avibactam susceptibility testing for highly resistant MBL-producing Enterobacterales
    Bhatnagar, Amelia
    Ransom, Eric M.
    Machado, Maria-Jose
    Boyd, Sandra
    Reese, Natashia
    Anderson, Karen
    Lonsway, David
    Elkins, Christopher A.
    Rasheed, J. Kamile
    Patel, Jean B.
    Karlsson, Maria
    Brown, Allison C.
    Lutgring, Joseph D.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2021, 76 (04) : 979 - 983
  • [37] Multicenter Study of Outcomes with Ceftazidime-Avibactam in Patients with Carbapenem-Resistant Enterobacteriaceae Infections
    King, Madeline
    Heil, Emily
    Kuriakose, Safia
    Bias, Tiffany
    Huang, Vanthida
    El-Beyrouty, Claudine
    McCoy, Dorothy
    Hiles, Jon
    Richards, Lynette
    Gardner, Julianne
    Harrington, Nicole
    Biason, Kenneth
    Gallagher, Jason C.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2017, 61 (07)
  • [38] In vitro Activity of Cefiderocol and Ceftazidime-Avibactam, Against Carbapenemase-Producing Enterobacterales
    Ozyurt, Ozlem K.
    Tufanoglu, Pinar
    Cetinkaya, Ozgul
    Ozhak, Betil
    Yazisiz, Hatice
    Ongut, Gozde
    Turhan, Ozge
    Ogunc, Dilara
    CLINICAL LABORATORY, 2023, 69 (01) : 155 - 160
  • [39] In Vitro Activity of Imipenem-Relebactam, Meropenem-Vaborbactam, Ceftazidime-Avibactam and Comparators on Carbapenem-Resistant Non-Carbapenemase-Producing Enterobacterales
    Bonnin, Remy A.
    Bernabeu, Sandrine
    Emeraud, Cecile
    Naas, Thierry
    Girlich, Delphine
    Jousset, Agnes B.
    Dortet, Laurent
    ANTIBIOTICS-BASEL, 2023, 12 (01):
  • [40] Effect of ceftazidime-avibactam combined with different antimicrobials against carbapenem-resistant Klebsiella pneumoniae
    Wu, Yun
    Yu, Wei
    Chu, Xiaobing
    Zhang, Jingjia
    Jia, Peiyao
    Liu, Xiaoyu
    Zhu, Ying
    Xu, Yingchun
    Yang, Qiwen
    MICROBIOLOGY SPECTRUM, 2024, 12 (06):